Exploring the Growth Potential of the Indian Pharmaceutical Sector
Sector Performance and Outlook
Top Companies Analysts Recommend Based on Upside Potential
Company Name Current Price Target Price Upside Potential Recommendation Cohance Lifesciences Limited Rs. 1065.4 Rs. 1400.00 33% Strong Buy Piramal Pharma Rs. 205.74 Rs. 271.00 32% Strong Buy Natco Pharma Rs. 870.1 Rs. 1090.00 28% Hold Aurobindo Pharma Rs. 1182 Rs. 1470.00 23% Buy Blue Jet Healthcare Rs. 794.3 Rs. 943.00 19% Buy Zydus Lifesciences Rs. 906.65 Rs. 1040.00 18% Hold
Cohance Lifesciences
Live Events
Piramal Pharma
Natco Pharma
Aurobindo Pharma
Blue Jet Healthcare
Zydus Lifesciences
(You can now subscribe to our
(You can now subscribe to our ETMarkets WhatsApp channel
The Indian pharmaceutical sector has demonstrated a robust growth trajectory, with a notable increase in performance over the past year. The sector has benefitted from a new trade agreement with the European Union, which aims to reduce tariffs on key drug exports. This agreement is expected to enhance India's position as a global supplier of generic medicines , leading to increased trade volume and job creation within the sector.In the short term, the sector has shown positive momentum, reflecting a steady rise in investor confidence. The long-term implications of the trade agreement include improved access to European markets and potential technology transfer, which could significantly bolster India's pharmaceutical innovation capabilities. Overall, the outlook for the sector remains positive, with analysts projecting substantial upside potential for various companies operating within this space. Cohance Lifesciences Limited , formerly known as Suven Pharmaceuticals Limited, is a technology-driven contract development and manufacturing organization(CDMO)based in India. The company specializes in providing integrated solutions in custom synthesis, process research and development, and manufacturing. Its business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient(API)services.Analysts have a strong buy recommendation for Cohance Lifesciences, with a target price of Rs. 1400.00, indicating an upside potential of 33%. The company has shown impressive financial performance, with a year-on-year PAT growth of 77.27%, despite a slight decline in sales growth of 21.56%. Piramal Pharma Limited is a global pharmaceutical company offering a diverse portfolio of differentiated pharma products across a domestic and global distribution network. The company operates approximately 17 development and manufacturing facilities across India, the UK/Europe, and North America.With a strong buy recommendation from analysts, Piramal Pharma has a target price of Rs. 271.00, reflecting an upside potential of 32%. The latest financial data shows a sales growth of 11.99% year-on-year, although the PAT stands at Rs. 153.5 Cr. Natco Pharma Limited is an India-based vertically integrated pharmaceutical company focused on research and development. The company specializes in developing, manufacturing, and commercializing complex pharmaceuticals targeting specific therapeutic areas.Analysts recommend holding Natco Pharma, with a target price of Rs. 1090.00, indicating an upside potential of 28%. The latest financial results reveal a significant year-on-year sales growth of 47.72%, although PAT has decreased by 37.47% compared to the previous year. Aurobindo Pharma Limited is engaged in the manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, and generic pharmaceuticals. The company has a global presence, marketing its products in approximately 150 countries.With a buy recommendation from analysts, Aurobindo Pharma has a target price of Rs. 1470.00, reflecting an upside potential of 23%. The company reported a year-on-year sales growth of 16.68%, although PAT has decreased by 9.66% in the latest quarter. Blue Jet Healthcare Limited specializes in manufacturing integrated contrast media, artificial sweeteners, and niche pharmaceutical intermediaries. The company operates primarily as a business-to-business entity, serving various industries globally.Analysts have a buy recommendation for Blue Jet Healthcare, with a target price of Rs. 943.00, indicating an upside potential of 19%. The company has demonstrated remarkable financial growth, with a year-on-year PAT growth of 177.64% and sales growth of 44.74%. Zydus Lifesciences Limited is a global life sciences company engaged in discovering, developing, manufacturing, and marketing a broad range of healthcare therapies. The company has a diverse product portfolio, including active pharmaceutical ingredients and human formulations.Analysts recommend holding Zydus Lifesciences, with a target price of Rs. 1040.00, reflecting an upside potential of 18%. The company has reported a year-on-year sales growth of 18.9%, although PAT has decreased by 5.79% in the latest quarter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
32 minutes ago
- Indian Express
First stop in France, Jaishankar embarks on week-long trip to Europe
External Affairs Minister S Jaishankar on Sunday embarked on a week-long visit to Europe to hold talks with leaders of France, the European Union and Belgium to boost bilateral ties and reaffirm India's policy of zero-tolerance against terrorism. Jaishankar's visit to Europe comes a month after India launched Operation Sindoor in response to the dastardly Pahalgam terror attack and it is expected that he will apprise the European leaders about New Delhi's firm approach in dealing with cross-border terrorism. In the first leg of his tour, Jaishankar will visit France, a country that has emerged as an all-weather friend of New Delhi. 'The external affairs minister would travel to Paris and Marseille where he would be holding bilateral discussions with his counterpart minister for Europe and Foreign Affairs Jean Noel Barrot,' the Ministry of External Affairs (MEA) said. Jaishankar would also participate in the inaugural edition of the Mediterranean Raisina Dialogue to be held in the city of Marseille. In Brussels, Jaishankar will hold a strategic dialogue with the EU High Representative and Vice President Kaja Kallas. 'India-European Union strategic partnership has strengthened over the years across diverse sectors and got a big boost with the first-ever visit of the EU College of Commissioners to India in February this year,' the MEA said. Jaishankar will engage also with the senior leadership from the European Commission and the European Parliament, besides interacting with think tank and media. In the third and final leg of his visit, the external affairs minister will hold wide-ranging talks with leaders of Belgium. 'India and Belgium share warm and friendly relations along with a very robust economic partnership. Today, the collaboration between the two countries spans various domains like trade and investment, green energy, technology, pharmaceutical, diamond sector and strong people-to-people ties,' the MEA said. It said Jaishankar would hold bilateral consultations with the Deputy Prime Minister and Foreign Minister of Belgium Maxime Prevot and would also meet the senior leadership of the country. He will also interact with the members of the Indian community.
Time of India
36 minutes ago
- Time of India
Why Harvard is easier to crack than IITs or IIMs for Indian students
U.S. President Donald Trump has halted funding to universities it disagrees with ideologically and temporarily suspended visa interviews required for foreign students planning to enroll this year. This move directly impacts Indian students, who make up nearly one-third of all international students in the United States, as per The Economist report. India has been losing academic talent to America for decades. At the famed Indian Institutes of Technology (IITs), over 60% of the top 100 performers migrate abroad, mostly for America. ALSO READ: Harvard University scores legal win against Trump's international student ban (Join our ETNRI WhatsApp channel for all the latest updates) The Economist report says that Trump's policies might cause Indian students' applications to American universities to plummet by a quarter from this year to the next. Live Events Easier to get into Harvard India is home to half the world's university-age population. On paper, India's top universities have a lot to offer. But getting into them is much harder—some accept as few as 0.2% of applicants, compared to 3–9% for Ivy League schools like Harvard , as per The Economist. Meanwhile, after Trump's stark steps, many parents who had been set on sending their children to the US are rethinking their plans. ALSO READ: Harvard vs Trump: As fresh salvos are fired, international students live in anxiety and fear Looking for options Indian students primarily went to the US to study STEM subjects – science, technology, engineering and maths – and so the focus had shifted to other countries strong in these areas, Piyush Bhartiya, a co-founder of the educational technology company AdmitKard told the Guardian. 'Germany is the main country where students are shifting to for Stem subjects,' he said. 'Other countries like Ireland, France, the Netherlands, which are also gaining substantial interest in the students. At the undergraduate level, the Middle East has also seen a lot of gain in interest given parents feel that it is close by and safer and given the current political environment they may want their kids closer to the home.' ALSO READ: Trump's birthright citizenship order to face first US appeals court review What is happening at Harvard? Harvard University has sued the Trump administration to preserve its ability to enroll international students and restore draconian cuts in research money, two matters that threaten the core functions of the centuries-old institution. The same federal judge in Massachusetts, Allison Burroughs, an appointee of President Barack Obama, is presiding over both cases. She has often sided with Harvard, including on Thursday when she issued a temporary restraining order against the administration's latest move to bar international students. On both fronts, the Trump administration has said that it is punishing Harvard because it has failed to keep Jewish students safe by allowing antisemitism to flourish. It has added on to these accusations as the court fights have drawn on, saying that the university has used racial preferences in admissions in defiance of a Supreme Court ruling and that it has broken rules related to foreign gifts. Harvard has denied the accusations. It says the administration is ignoring its efforts to protect the civil rights of its Jewish students, for example. And Harvard has argued that the federal government has violated its First Amendment rights and has ignored due process as it pursues its vendetta against the university.
Mint
40 minutes ago
- Mint
Stocks to buy for short term: From Praj Industries to Route Mobile— Jigar Patel of Anand Rathi suggests 3 stock picks
Stocks to buy for the short term: A deeper-than-expected 50 bps rate cut drove the Indian stock market benchmark Nifty 50 above the 25,000 mark on Friday, June 6. The index ended the week over a per cent higher, snapping its two-week losing run. According to Jigar S. Patel, Senior Manager of Equity Research at Anand Rathi Share and Stock Brokers, the Nifty 50 is approaching a critical resistance zone of 25,100–25,300, aligning with key Fibonacci retracement levels. Patel believes this zone may trigger profit booking and poses a risk of negative RSI divergence on the daily chart. "We remain cautious and recommend profit-booking near this zone. A decisive breakout above 25,300 could warrant a re-evaluation of our outlook," said Patel. "On the downside, 24,700 serves as immediate support, while 24,450 remains the make-or-break level for bulls. The coming week's follow-through will determine whether this bounce sustains or fizzles out," Patel said. Jigar Patel recommends buying shares of Route Mobile, Praj Industries and OFSS for the next two to three weeks. In the recent trading session, Route Mobile broke out after nearly a month of consolidation, accompanied by a significant surge in volume, indicating strong accumulation. This consolidation phase is particularly notable because it occurred within the R3–S3 zone of the monthly Camarilla pivots, establishing an inside-value relationship. This setup forms when the current month's pivots are nested within the previous month's range, often signalling a potential breakout with strong directional bias. Adding to the bullish case, the daily RSI has consistently held above the 40 level and is now positioned at 64, reflecting strengthening momentum. "We recommend a buying opportunity in the ₹ 1,000–1,030 zone, with a target price of ₹ 1,150 and a stop loss of ₹ 940 on a daily closing basis," said Patel. Route Mobile stock technical chart Praj Industries has recently completed a bullish dragon pattern, indicating the potential for a strong upward move. Complementing this setup, the monthly Camarilla pivots are displaying a higher overlapping value relationship, and price action has decisively closed above the R3 level—a clear signal of emerging bullish momentum. On the momentum front, the daily RSI has broken out after a prolonged consolidation between the 40–50 zone and now stands near 60, reinforcing the positive bias. "Initiate long positions in the ₹ 500–508 zone, with the target price of ₹ 580 and a stop loss of ₹ 465 on a daily closing basis," said Patel. Praj Industries stock technical chart OFSS has recently formed a solid base in the ₹ 8,300–8,700 range and is now trading firmly above the ₹ 8,700 mark, suggesting growing strength. What stands out technically is the presence of an inside value relationship between the monthly Camarilla R3 and S3 pivots—a structure that often precedes sharp directional moves. Adding to the bullish setup, the daily RSI has consistently held the 50 level, reflecting sustained momentum and the potential for a continued uptrend. "Enter long positions in the ₹ 8,700–8,800 zone, with the target price of ₹ 9,800 and a stop loss of ₹ 8,250 on a daily closing basis," said Patel. OFSS stock technical chart Read all market-related news here Read more stories by Nishant Kumar Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions, as market conditions can change rapidly, and circumstances may vary.
